AKT1 and lung carcinoma: YY1 upregulates the secretion of IL-32 in pericytes and subsequently activates the β5-integrin-Src-Akt (protein kinase B) pathway in EGFR-mutated lung cancer cells, thereby influencing sensitivity to TKIs [129].